Joey's Wings Foundation

We fund research on MiT family translocation renal cell carcinoma in children and young adults.

[Joey's Wings Foundation @Joeyswings]

@Cary_Weiss @ConquerCancerFd Congratulations on your award! This recognition is so well deserved.

[Joey's Wings Foundation @Joeyswings]

Another year of sponsoring young investigators from kidney cancer community to attend 2026 AACR. May this experience broaden their perspectives, deepen their learning, and inspire them to pursue meaningful careers in cancer research!

[Joey's Wings Foundation @Joeyswings]

Thank you @DrRanaMcKay for a day focusing on patients: updates on research & clinical trials, dietary advice, survivors stories…

[Nancy Goodman @NancyFGoodman]

https://t.co/DeRH0Sfacr

SENATE: PASS THE MIKAELA NAYLON GIVE KIDS A CHANCE ACT!
@SenSchumer
@LeaderJohnThune
@SenSanders
@PattyMurray
@SenatorBaldwin
@timkaine
@ChrisMurphyCT
@SenatorAndyKim
@SenLBR

[Joey's Wings Foundation @Joeyswings]

https://t.co/qz5TJM6pVh

[Joey's Wings Foundation @Joeyswings]

RNA binding by TFE3 fusion partners facilitates biomolecular condensate formation, which enhances RNAPII activity to drive pro-oncogenic transcriptional programs. PSPC1 is identified as a key co-condensate component. Can we dissolute TFE3 onco-
fusion condensates?

[Joey's Wings Foundation @Joeyswings]

Please pass the Mikaela Naylon Give Kids a Chance Act without delay.@SenSanders
@SenMurray
@Hickenlooper
@ChrisMurphyCT
@SenatorHassan
@Sen_Alsobrooks
@SenLBR
@SenatorAndyKim
@SenatorBaldwin
@SenMarkey
@timkaine81458

[Prathyusha Konda ✨ @labratprats]

Despite distinct genetic and transcriptional programs, tRCC and ccRCC share a VCAM1⁺ proximal tubule origin. Some tRCCs, however, may arise from other kidney lineages - plasticity that could explain its varied histology and presence of TFE3 fusions in ASPS and PEComa.

[Joey's Wings Foundation @Joeyswings]

Our Florida team is the best! The 11th annual Joey’s Wings 5k was a success!

[Kaushal Asrani @AsraniKaushal]

Excited to finally share our latest study on #TranslocationRCC #PEComas @NatureComms!
We generated the first ever, murine transgenic kidney tumor models of SFPQ-TFE3 - the most common MiT/TFE gene fusion implicated in both, tRCC and PEComas (Perivascular Epitheloid neoplasms).
We describe a novel role for this fusion in regulating #mTORC1-driven lineage plasticity, with transcriptional downregulation of critical nephric lineage transcription factors like PAX8, that perfectly recapitulate human renal PEComas.
Additionally, we nominate the lysosomal V-ATPase complex as a central regulator of mTORC1 activity in tRCC, and a target-rich environment for therapeutic intervention in this deadly disease.
Grateful to all the co-authors, collaborators, reviewers, editors and funding sources who made this study possible! @adriannaamendes @LotanLab @eddieimada @MasayaBaba2 @terry_watnickmd @WMarstonLinehan @PeterArgani @yasserged @rmelias2 @nirmishsingla @allaf_mo @Joeyswings @KidneyCancer @kidneycan @CDMRP
https://t.co/3kcO1TWmNI

[Joey's Wings Foundation @Joeyswings]

7 meetings in a day. Rallying for KCRP under CDMRP. We refuse to go backward!

[Gabriel Malouf @GabrielMalouf]

The Malouf Lab at IGBMC (Strasbourg, France) is recruiting a postdoctoral researcher to join a translational research program focused on rare and treatment-resistant kidney cancers.

🔗 Full details here: https://t.co/0Hupu6AnUK
Let’s build something meaningful @SPBassociation

[Joey's Wings Foundation @Joeyswings]

Life can be incredibly cruel. 14, what a beautiful age. Austen from Missouri was diagnosed with TFE3 rearranged PEComa overlapping with tRCC only 5 months ago. She passed away this morning. This hurts like hell.

[Joey's Wings Foundation @Joeyswings]

Much respect to @srviswanathan recipient of Kidney Cancer Innovation/Discovery Grants! Rare subtype like tRCC often received less funding and attention. It takes dedication, creativity, and compassion to tackle diseases that are poorly understood and harder to treat. #KCRS25

[Michael Serzan, MD @MikeSerzanMD]

🗣️Kidney Cancer Oral Abstracts #ASCO25

👉Abs4521: Dr #JAmesGeller presenting Nivo/Axitinib vs Nivo in pts with translocation RCC #AREN1721

🩺Clinical implications:
- Nivo/Axitinib (n=6) showed early efficacy ORR 33% and mPFS 10mo
- #TranslocationRCC remains a disease of unmet need

Further Reading
📖Integrative clinical and molecular characterization of translocation renal cell carcinoma @ZiadBakouny @srviswanathan
🔗https://t.co/IqCRymfDpq

📖A genetic basis for sex differences in Xp11 translocation renal cell carcinoma @m_achom
🔗https://t.co/yFVOywmvre
--------------------------------------------------------
n = 13
Median Age 16 (7-42)
9/13 under 18yo, 9/13 male

💉 Nivo + Axitinib (n=6) ORR 33% mPFS 10.5mo
💉 Nivo alone (n=5) ORR 0%. mPFS 1.8mo
💉 Axitinib alone (n=2) ORR 0%

👥@DrChoueiri @montypal @AlbigesL @TiansterZhang @DrRanaMcKay @tompowles1 @brian_rini @BraunMDPhD @DrKarieRuncie @PBarataMD @PavlosMsaouel @yekeduz_emre @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @ReginaBarCar @crisbergerot @kidneycan @KidneyCancer @ASCO @oncoalert @OncBrothers

[James Brugarolas @JBrugarolas]

Delighted to host @KidneyCancer model workshop @KCPUTSW

[Danfeng Cai @DanfengCai]

Press release on our recent TFE3 fusion condensate paper.
https://t.co/dW8XGdYpXn

[UC San Diego Health Moores Cancer Center @UCSDCancer]

Another peek into the transformative Kidney Cancer Patient Summit — where stories, science and support came together.

Thank you to @Joeyswings for the videography and support: https://t.co/3clodRhPoS.

[Joey's Wings Foundation @Joeyswings]

@GabrielMalouf @DrPrateekKhanna @EmboMolMed @IGBMC @unistra @srviswanathan The enrichment in myCAFs was associated with primary resistance to ICI therapy in the BIONIKK clinical trial.

[Gabriel Malouf @GabrielMalouf]

Our latest study in @EmboMolMed reveals how TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma (tRCC). We define tRCC as a novel metabolic subtype of renal cancer. @IGBMC @unistra @srviswanathan
🔗https://t.co/v2unMxB9KO